Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

569 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations.
Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, Herrmann J, Porter C, Lyon AR, Lancellotti P, Patel A, DeCara J, Mitchell J, Harrison E, Moslehi J, Witteles R, Calabro MG, Orecchia R, de Azambuja E, Zamorano JL, Krone R, Iakobishvili Z, Carver J, Armenian S, Ky B, Cardinale D, Cipolla CM, Dent S, Jordan K; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Curigliano G, et al. Among authors: orecchia r. Ann Oncol. 2020 Feb;31(2):171-190. doi: 10.1016/j.annonc.2019.10.023. Ann Oncol. 2020. PMID: 31959335 Free PMC article.
Male breast cancer: a special therapeutic problem. Anything new? (Review).
Gennari R, Curigliano G, Jereczek-Fossa BA, Zurrida S, Renne G, Intra M, Galimberti V, Luini A, Orecchia R, Viale G, Goldhrisch A, Veronesi U. Gennari R, et al. Among authors: orecchia r. Int J Oncol. 2004 Mar;24(3):663-70. Int J Oncol. 2004. PMID: 14767551 Review.
Optimization of the schedule of gemcitabine-cisplatin combination as induction regimen for patients with biopsy-proven stage IIIa N2 - stage IIIb non-small-cell lung cancer: a prospective phase-II study.
De Pas T, Curigliano G, Veronesi G, Catalano G, Catania C, Jereczek-Fossa B, Orecchia R, Spaggiari L, de Braud F. De Pas T, et al. Among authors: orecchia r. Bull Cancer. 2004 Sep 1;91(9):E273-7. Print 2004 Sep. Bull Cancer. 2004. PMID: 15582897 Free article. Clinical Trial.
Locoregional recurrence in patients with HER2 positive breast cancer.
Brollo J, Kneubil MC, Botteri E, Rotmensz N, Duso BA, Fumagalli L, Locatelli MA, Criscitiello C, Lohsiriwat V, Goldhirsch A, Leonardi MC, Orecchia R, Curigliano G. Brollo J, et al. Among authors: orecchia r. Breast. 2013 Oct;22(5):856-62. doi: 10.1016/j.breast.2013.03.010. Epub 2013 May 1. Breast. 2013. PMID: 23642529
High Ki67 predicts unfavourable outcomes in early breast cancer patients with a clinically clear axilla who do not receive axillary dissection or axillary radiotherapy.
Zurrida S, Bagnardi V, Curigliano G, Mastropasqua MG, Orecchia R, Disalvatore D, Greco M, Cataliotti L, D'Aiuto G, Talakhadze N, Goldhirsch A, Viale G. Zurrida S, et al. Among authors: orecchia r. Eur J Cancer. 2013 Oct;49(15):3083-92. doi: 10.1016/j.ejca.2013.05.007. Epub 2013 Jun 15. Eur J Cancer. 2013. PMID: 23777741 Clinical Trial.
Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
Curigliano G, Disalvatore D, Esposito A, Pruneri G, Lazzeroni M, Guerrieri-Gonzaga A, Luini A, Orecchia R, Goldhirsch A, Rotmensz N, Bonanni B, Viale G. Curigliano G, et al. Among authors: orecchia r. Ann Oncol. 2015 Apr;26(4):682-687. doi: 10.1093/annonc/mdv013. Epub 2015 Jan 18. Ann Oncol. 2015. PMID: 25600567 Free article. Clinical Trial.
569 results